Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck To Seek Prostate Cancer Claim For Proscar Despite Short Patent Life

Executive Summary

Merck intends to file a supplemental NDA for Proscar (finasteride) based on results from the National Cancer Institute's Prostate Cancer Prevention Trial
Advertisement

Related Content

GSK's Avodart To Get Panel Review For Prostate Cancer Prevention, With Merck's Proscar Along For The Ride
GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06
GSK Oncology Pipeline Expansion Means Healthy Phase III Program In ’06
Merck Will Launch New Proscar Indication During Last Week Of April
Merck Will Launch New Proscar Indication During Last Week Of April
Zocor Rx Growth Picks Up In June; Merck Hopes Crestor Helps Revive Market
Emend Risk Program To Ensure Prescribers Understand Approved Indication
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Advertisement
UsernamePublicRestriction

Register

PS042203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel